Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Human cells possess DNA repair mechanisms to prevent mutations and carcinogenesis.
• Defects in DNA repair are implicated in hereditary cancer syndromes like Lynch syndrome and BRCA-associated cancers.

Purpose of the Study:

• To review therapeutic strategies for DNA repair-deficient cancers, focusing on Lynch syndrome and BRCA-associated malignancies.
• To explore the role of DNA repair defects as therapeutic targets in these cancer types.

Main Methods:

• Review of current literature on DNA repair mechanisms and cancer therapy.
• Discussion of novel therapeutic agents, including poly (ADP-ribose) polymerase (PARP) inhibitors.
• Analysis of the tumor microenvironment and immune response in DNA repair-deficient cancers.

Main Results:

• DNA repair-deficient tumors exhibit increased sensitivity to platinum-based chemotherapy.
• PARP inhibitors demonstrate efficacy in tumors with homologous DNA repair deficiency.
• Patients with DNA repair deficiencies may have a more favorable prognosis compared to sporadic cancers.

Conclusions:

• Targeting DNA repair defects presents promising therapeutic avenues for Lynch syndrome and BRCA-associated cancers.
• The immune microenvironment, including CD8+ T cell recruitment and immune checkpoints, plays a role in the prognosis and treatment of these cancers.
• Future therapies may involve modulating immune checkpoints to enhance anti-tumor immunity in DNA repair-deficient malignancies.